SYRA
Syra Health CorpPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R May 7 Syra Health reported its first profitable quarter in Q1 2026, with n…
- X Jul 31 Short interest jumps 103.7% to 312.3K
- R Aug 11 Syra Health reports Q2 2026 results, its second consecutive profitab…
- X Sep 30 Short interest jumps 28.1% to 573.4K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q1 2025: 2 added (0 new), 1 trimmed or exited.
- TrendRANGE
2% above its 50-day average.
Who's buying
13F· Q1 2025| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $17.9K |
| UBS Group AG | DOUBLED | $5.1K |
| BANK OF AMERICA CORP /DE/ | TRIM | $20.00 |
| VANGUARD GROUP INC | TRIM | $13.7K |
| VANGUARD GROUP INC | ADD | $22.0K |
| BANK OF AMERICA CORP /DE/ | DOUBLED | $98.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 31, 2026 | Alexander Gregory R. CEO | AWARD | 368,458 sh |
| Aug 31, 2026 | Prasad Priya COO and CFO | AWARD | 26,009 sh |
| Aug 31, 2026 | Prasad Priya COO and CFO | AWARD | 60,687 sh |
| Aug 31, 2026 | Prasad Priya COO and CFO | AWARD | 86,696 sh |
| Aug 11, 2026 | Alexander Gregory R. CEO | AWARD | 368,458 sh |
| Jan 5, 2026 | Alexander Gregory R. CEO | AWARD | 110,537 sh |
| Jan 5, 2026 | Alexander Gregory R. CEO | AWARD | 257,920 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
6 filings · 2 bullish · 0 bearish · 4 neutral- NEUTRAL EFFECTOct 13, 2026
Syra Health Corp's S-1 registration statement (File No. 333-281583) became effective on October 9…
Monitor for any subsequent 8-K or 8-K filing announcing pricing or exercise of warrants; if warrants are exercised, dilution overhang materializes. Effectiveness typically precedes pricing by 1-2…
- NEUTRAL S-1Sep 14, 2026
Syra Health Corp. filed an S-1 registration statement to register 3,171,100 shares of Class A…
This S-1 is a routine resale registration with no immediate market impact, but it introduces potential overhang from the 3.17 million registered shares. Monitor for any cash exercise of the Series B…
- BULLISH 8-KAug 11, 2026
Syra Health reports Q2 2026 results, its second consecutive profitable quarter, with revenue up…
Syra Health has posted two consecutive profitable quarters with solid revenue growth and margin expansion, suggesting a potential inflection point. Monitor the Q3 report for sustainability of…
- NEUTRAL DEFA14AJun 1, 2026
Syra Health Corp filed a DEFA14A (additional definitive proxy soliciting materials) on June 1…
This DEFA14A appears to be a routine proxy solicitation filing with no material new information. Monitor for the definitive proxy statement (DEF 14A) for actual voting items and financial details…
All SYRA filing & press-release reports (6)
- EFFECT reportOct 13, 2026
- S-1 reportSep 14, 2026
- 8-K reportAug 11, 2026
- DEFA14A reportJun 1, 2026
- 8-K reportMay 7, 2026
- 10-K/A reportApr 24, 2026